专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007007060A3 N- OR C- TERMINALLY MODIFIED SMALL PEPTIDES 审中-公开
公开(公告)号：WO2007007060A3
公开(公告)日：2007-01-18
申请号：PCT/GB2006/002527
申请日：2006-07-07
申请人： ZEALAND PHARMA A/S , KIDDLE, Simon, John , LARSEN, Bjarne Due , KERNS, Edward, H.
发明人： LARSEN, Bjarne Due , KERNS, Edward, H.
IPC分类号： C07K5/06 , A61K38/00
摘要： N- or C-terminally modified small peptides having antiarrhythmic properties are disclosed, and in particular to small peptides that possess improved pharmacokinetic properties such as have a reduced tendency to inhibit the activity of isozyme 3A4 of cytochrome P 450 oxidase. The invention further relates to uses of said compounds in the preparation of a medicament, and to pharmaceutical compositions comprising said compounds.

2. 发明申请

WO2011088837A1 TREATMENT OF CARDIAC CONDITIONS 审中-公开
标题翻译：治疗心脏病症状
公开(公告)号：WO2011088837A1
公开(公告)日：2011-07-28
申请号：PCT/DK2011/050018
申请日：2011-01-20
申请人： ZEALAND PHARMA A/S , PETERSEN, Jørgen Søberg , KJOELBYE, Anne Louise , SKOVGAARD, Marie , PEDERSEN, Henrik Duelund , AXELSEN, Lene , RIBER, Ditte , MEIER, Eddi , HANSEN, Rie Schultz , FOSGERAU, Keld , LARSEN, Bjarne Due
发明人： PETERSEN, Jørgen Søberg , KJOELBYE, Anne Louise , SKOVGAARD, Marie , PEDERSEN, Henrik Duelund , AXELSEN, Lene , RIBER, Ditte , MEIER, Eddi , HANSEN, Rie Schultz , FOSGERAU, Keld , LARSEN, Bjarne Due
IPC分类号： A61K38/26 , A61P9/04
CPC分类号： C07K14/605 , A61K38/26 , C07K14/4705
摘要： The invention relates to the treatment of cardiac dysfunction. In particular, certain compounds, believed to be glucagon-GLP-1 dual agonist compounds, exert a positive inotropic effect while preserving the energy balance of the heart, and so may be superior to known inotropic agents such as dobutamine, norepinephrine and glucagon.
摘要翻译：本发明涉及心脏功能障碍的治疗。特别地，被认为是胰高血糖素GLP-1双重激动剂化合物的某些化合物在保持心脏能量平衡的同时发挥正性肌力作用，因此可以优于已知的肌力药如多巴酚丁胺，去甲肾上腺素和胰高血糖素。

3. 发明申请

WO2010142293A1 COMPOUNDS ACTING AS PEPTIDE GAP JUNCTION MODULATORS, AND USES THEREOF 审中-公开
标题翻译：作为肽桥接调制器的化合物及其用途
公开(公告)号：WO2010142293A1
公开(公告)日：2010-12-16
申请号：PCT/DK2010/000092
申请日：2010-06-11
申请人： ZEALAND PHARMA A/S , DELMAR, Mario , TAFFET, Steven M. , COOMBS, Wanda , VERMA, Vandana , LARSEN, Bjarne Due , THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK , THE REGENTS OF THE UNIVERSITY OF MICHIGAN
发明人： DELMAR, Mario , TAFFET, Steven M. , COOMBS, Wanda , VERMA, Vandana , LARSEN, Bjarne Due
IPC分类号： A61K38/12 , C07K7/64
CPC分类号： G01N33/5032 , A61K38/00 , C07K7/64
摘要： Compounds capable of modulating intracellular gap junctional communication, as well as their use in the treatment of diseases associated with impaired gap junction intracellular communication (GJIC)1 are disclosed.
摘要翻译：公开了能够调节细胞间隙连接通讯的化合物及其在治疗与间隙连接细胞内通讯（GJIC）1相关的疾病中的用途。

4. 发明申请

WO2010070252A1 GLUCAGON ANALOGUES 审中-公开
标题翻译：胰高血糖素类似物
公开(公告)号：WO2010070252A1
公开(公告)日：2010-06-24
申请号：PCT/GB2008/004130
申请日：2008-12-15
申请人： ZEALAND PHARMA A/S , MEIER, Eddi , RIBER, Ditte , SKOVGAARD, Marie , LARSEN, Bjarne Due , DAUGAARD, Jens Rosengren , FORREST, Graham
发明人： MEIER, Eddi , RIBER, Ditte , SKOVGAARD, Marie , LARSEN, Bjarne Due , DAUGAARD, Jens Rosengren
IPC分类号： C07K14/605
CPC分类号： C07K14/605 , A61K38/00
摘要： The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
摘要翻译：本发明提供促进体重减轻或预防体重增加的材料和方法，以及用于治疗糖尿病，代谢综合征和相关病症的材料和方法。特别地，本发明提供了在这些方法中有效的新型胰高血糖素类似物肽。与人胰高血糖素相比，肽可以通过提高对GLP-1受体的选择性来介导它们的作用。

5. 发明申请

WO2009010733A2 PEPTIDE GAP JUNCTION MODULATORS 审中-公开
标题翻译：肽阻塞调节器
公开(公告)号：WO2009010733A2
公开(公告)日：2009-01-22
申请号：PCT/GB2008/002405
申请日：2008-07-14
申请人： ZEALAND PHARMA A/S , THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK , KIDDLE, Simon J. , LARSEN, Bjarne Due , DELMAR, Mario , TAFFET, Steven M , COOMBS, Wanda , VERMA, Vandana
发明人： LARSEN, Bjarne Due , DELMAR, Mario , TAFFET, Steven M , COOMBS, Wanda , VERMA, Vandana
IPC分类号： C07K5/02 , C07K5/10 , C07K7/06 , C07K7/08 , C07K14/00 , A61K38/07 , A61K38/08 , A61K38/10 , A61K38/16
CPC分类号： C07K14/705 , A61K38/00 , C07K5/0817 , C07K5/1019
摘要： Disclosed are peptides that facilitate the intercellular communication mediated by gap junctions. The invention has a wide spectrum of useful applications including use in the treatment of diseases associated with impaired gap junction intracellular communication (GJIC).
摘要翻译：公开了促进由间隙连接介导的细胞间通讯的肽。本发明具有广泛的有用应用，包括用于治疗与间隙连接细胞内通讯（GJIC）相关的疾病。

6. 发明申请

WO2008056155A1 SELECTIVE GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES 审中-公开
标题翻译：选择性GLUCAGON-LIKE-PEPTIDE-2（GLP-2）ANALOGUES
公开(公告)号：WO2008056155A1
公开(公告)日：2008-05-15
申请号：PCT/GB2007/004273
申请日：2007-11-08
申请人： ZEALAND PHARMA A/S , LARSEN, Bjarne Due , PETERSEN, Yvette Miata
发明人： LARSEN, Bjarne Due , PETERSEN, Yvette Miata
IPC分类号： C07K14/605 , A61K38/26
CPC分类号： C07K14/605 , A61K38/26 , A61K45/06
摘要： GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an increased small intestine/colon and stomach/colon selectivity. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions (11, 16, 20, 24) and/or (28) of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position (2) and one or more of positions (3, 5, 7), and (10), and/or a deletion of one or more of amino acids (31) to (33) and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy.
摘要翻译： GLP-2类似物被公开，其包含与h [Gly2] GLP-2相比更多的取代，并且其可具有增加的小肠/结肠和胃/结肠选择性的性质。更具体地，本文公开的优选的GLP-2类似物在野生型GLP-2序列的一个或多个位置（11,16,20,24）和/或（28）处包含取代，任选地与位置（2）和位置（3,5,7）和（10）中的一个或多个，和/或一个或多个氨基酸（31）至（33）的缺失和/或添加N 末端或C-末端稳定肽序列。类似物对于预防或治疗胃和肠相关疾病以及改善化学疗法的副作用特别有用。

7. 发明申请

WO2007022774A1 THERAPEUTICALLY ACTIVE α-MSH ANALOGUES 审中-公开
标题翻译：治疗有效的a-MSH类似物
公开(公告)号：WO2007022774A1
公开(公告)日：2007-03-01
申请号：PCT/DK2005/000545
申请日：2005-08-26
申请人： ACTION PHARMA A/S , JONASSEN, Thomas, Engelbrecht, Norkild , NIELSEN, Søren , FRØKIÆR, Jørgen , LARSEN, Bjarne Due
发明人： JONASSEN, Thomas, Engelbrecht, Norkild , NIELSEN, Søren , FRØKIÆR, Jørgen , LARSEN, Bjarne Due
IPC分类号： C07K14/685 , A61K38/34 , A61P29/00
CPC分类号： C07K7/08 , C07K14/685 , C07K2319/31
摘要： The invention describes peptide analogues of a-melanocyte-stimulating hormone (a-MSH), which posses an increased efficay compared to the native α-MSH peptide. The α-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to α-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.
摘要翻译：本发明描述了与天然a-MSH肽相比，其具有增加的效力的α-黑素细胞刺激激素（a-MSH）的肽类似物。与a-MSH相比，a-MSH类似物表现出增加的抗炎作用和增强的预防缺血状况的能力。本发明进一步公开了该肽用于制备用于治疗或预防哺乳动物的一种或多种器官的组织中的病症的药物组合物的用途，以及药物组合物。

8. 发明申请

WO2016066744A2 GIP AGONIST COMPOUNDS AND METHODS 审中-公开
标题翻译： GIP激进化合物和方法
公开(公告)号：WO2016066744A2
公开(公告)日：2016-05-06
申请号：PCT/EP2015/075120
申请日：2015-10-29
申请人： ZEALAND PHARMA A/S
发明人： SHELTON, Pernille Tofteng , NØRREGAARD, Pia , DERYABINA, Maria Alexandrovna , LARSEN, Bjarne Due , FOG, Jacob Ulrik
IPC分类号： A61K38/26 , C07K14/605
CPC分类号： C07K14/575 , A61K38/00
摘要： The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.
摘要翻译：本发明涉及具有GIP激动剂活性的酰化GIP类似物，以及它们在治疗代谢性疾病中的用途。

9. 发明申请

WO2018202865A1 GAP JUNCTION INTERCELLULAR COMMUNICATION MODULATORS AND THEIR USE FOR THE TREATMENT OF DIABETIC EYE DISEASE 审中-公开
公开(公告)号：WO2018202865A1
公开(公告)日：2018-11-08
申请号：PCT/EP2018/061537
申请日：2018-05-04
申请人： ZEALAND PHARMA A/S , BOSTON MEDICAL CENTER CORPORATION
发明人： LARSEN, Bjarne Due , MOURITZEN, Ulrik , KIM, Dongjoon , ROY, Sayon
IPC分类号： A61K38/08 , A61K31/4025 , A61P9/10
摘要： The use of gap junction intercellular communication (GJIC) modulators in the treatment or prevention of diabetic eye disease is disclosed, and more particularly to their use for the treatment or prevention of early stage diabetic retinopathy and diabetic macular edema by inhibiting apoptosis of retinal endothelial cells and inhibiting pericyte loss.

10. 发明授权

EP2051995B1 SELECTIVE GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES 有权
标题翻译：的选择性ANALOG胰高血糖素样肽-2（GLP-2）
公开(公告)号：EP2051995B1
公开(公告)日：2017-02-08
申请号：EP07824505.7
申请日：2007-11-08
申请人： Zealand Pharma A/S
发明人： LARSEN, Bjarne Due , PETERSEN, Yvette Miata
IPC分类号： C07K14/605 , A61K38/26
CPC分类号： C07K14/605 , A61K38/26 , A61K45/06

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式